Copyright © 2019. Inderes Oy. All rights reserved.
Faron Pharmaceuticals
1862 investors follow this company
The company is not covered. See all listed companies from here.
BUY 3.34 LOWEST 3.33 VOLUME 9 255
SELL 3.35 HIGHEST 3.44 VALUE 0,031 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Analyst

Latest insider trading

Net impact profile

Stock release
16.10.
2020

WHO concludes that subcutaneous IFN beta-1a is ineffective in hospitalized COVID-19 patients

Faron Pharmaceuticals Oy
("Faron" or the "Company")

Company announcement, 16 October 2020 at 1.35 PM (EEST)
 

Stock release
14.10.
2020

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that the Company's board has confirmed the grant of a total of 690,333 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019. The Options have been allocated under the Share Option Plan 2019 and are exercisable between 23 July 2021 and 23 July 2025 at an exercise price of €3.80 per share (£3.44), vesting 25% per annum over a period of four years.

Stock release
30.9.
2020

NOTIFICATION OF MAJOR HOLDINGS

[][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]

Stock release
24.9.
2020

Issue of equity

Company announcement, 24 September 2020 at 9.15 (EEST)

Stock release
24.9.
2020
  • Development of novel cancer immunotherapy Clevegen[®] (bexmarilimab) continues in Phase I/II MATINS trial across 10 tumour types
  • IV interferon beta-1a, Traumakine[®], being investigated as potential COVID-19 treatment in two ongoing global trials with preparations for US trial underway
  • Successful €14 million placing in April strengthens Company's balance sheet
  • Additional grants of €3.3 million and €4.6 million loans awarded to drive R&D and CMC programmes

Half-year report, 24 September 2020 at 9.00 AM (EEST)

Stock release
18.9.
2020

Data from completed Part I of bexmarilimab MATINS trial presented at ESMO Virtual Congress 2020

TURKU - FINLAND, 18 September 2020 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announces details from an oral presentation being held at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, showcasing data from the Company's ongoing MATINS trial to the scientific community.

Stock release
27.8.
2020

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Company announcement, 27 August 2020 at 9.00 AM (EET)

TURKU - FINLAND, 27 August 2020 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, will announce its unaudited half-year report for the six months ended 30 June 2020 on Thursday 24 September 2020.

Stock release
18.8.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

  • €2.5 million loan guarantee from Finnvera to further expand IV IFN beta-1a manufacturing process
  • AGC Biologics selected as new commercial scale manufacturer
  • COVID-19 trials continue to investigate Traumakine treatment

Company announcement, 18 August 2020 at 9.00 AM (EET)
Insider information

Stock release
27.7.
2020

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Company announcement, 27 July 2020 at 9.00 AM (EET)

TURKU - FINLAND, 27 July 2020 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce that Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company with immediate effect.  Panmure Gordon (UK) Limited continues to act as the Company's Broker.

For further information, please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

Stock release
8.7.
2020

("Faron" or the "Company")

Company announcement, 8 July 2020 at 5 PM (EEST)

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company.

Faron Pharmaceuticals

English translation unavailable for Faron Pharmaceuticals.